Back to top
more

Avid Bioservices (CDMO)

(Delayed Data from NSDQ)

$10.27 USD

10.27
494,093

+0.31 (3.11%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $10.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

by Zacks Equity Research

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

by Zacks Equity Research

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

Glaxo's (GSK) Q1 Earnings In Line, Sales Hit by COVID-19

by Zacks Equity Research

Glaxo's (GSK) revenues get hurt by disruption related to COVID-19 pandemic. However, robust growth in respiratory, immuno-inflammation and cancer drugs partially offset the decline.

Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings

by Zacks Equity Research

AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).

Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag

by Zacks Equity Research

FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

by Zacks Equity Research

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma

by Zacks Equity Research

Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma

Shrabana Mukherjee headshot

5 Stocks to Buy on New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

Benjamin Rains headshot

Find Strong Stocks to Start Q2 with New Analyst Coverage

by Benjamin Rains

One way to find potential winners is to search for companies that have landed new analyst coverage recently. And the reasoning is pretty straightforward...

Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).

QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA

by Zacks Equity Research

QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.

Zacks.com featured highlights include: UFP Industries, Interactive Brokers Group, Avid Bioservices, Amtech Systems and Gaia

by Zacks Equity Research

Zacks.com featured highlights include: UFP Industries, Interactive Brokers Group, Avid Bioservices, Amtech Systems and Gaia

Shrabana Mukherjee headshot

These 5 Stocks Are Safe Bets Courtesy of New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Interactive Brokers (IBKR), Avid (CDMO), Amtech (ASYS) and GAIA

Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes

by Zacks Equity Research

Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.

Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable

by Zacks Equity Research

Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.

Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon

Avid Bioservices (CDMO) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 150.00% and 9.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 6.8%

by Zacks Equity Research

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Avid Bioservices (CDMO) Catches Eye: Stock Jumps 5.4%

by Zacks Equity Research

Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.

Analysts Estimate Avid Bioservices (CDMO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Mar 12, 2020

by Zacks Equity Research

Companies In The News Are: TLSA, VIR, HEAR, CDMO

Avid Bioservices (CDMO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -100.00% and -19.14%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?